15:40 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Accelerate raises $150M in note offering

In vitro diagnostic company Accelerate Diagnostics Inc. (NASDAQ:AXDX) raised $150 million on March 23 through the sale of 2.5% convertible senior notes due 2030 in a private placement. The notes have an initial conversion price...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the continued...
04:41 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

PhenoTest BC Kit regulatory update

FDA approved the PhenoTest BC Kit from Accelerate to identify infectious organisms from blood and provide information on the antibiotic sensitivity of those organisms. The product was approved through the de novo premarket review pathway....
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Accelerate ID/AST Blood Culture Assay: Pilot trial data

A pilot study of 146 positive blood culture samples and 127 samples seeded with challenging bacterial or fungal isolates showed that ID/AST Blood Culture Assay had an overall sensitivity of 96.6% and specificity of 99.4%...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Financial News

Accelerate Diagnostics financial update

Accelerate Diagnostics Inc. (NASDAQ:AXDX), Tucson, Ariz.   Business: Supply/Service, Diagnostic   Date announced: 2015-12-15   Note: Accelerate raised $14.2 million through the sale of 838,235 shares at $17 to cover the overallotment from its Dec. 9, 2015, follow-on,...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Financial News

Accelerate Diagnostics completes follow-on

Accelerate Diagnostics Inc. (NASDAQ:AXDX), Tucson, Ariz.   Business: Supply/Service, Diagnostic   Date completed: 2015-12-09   Type: Follow-on   Raised: $95 million   Shares: 5.6 million   Price: $17   Shares after offering: 50.3 million   Underwriters: JPMorgan; Piper Jaffray; William Blair; BTIG   Overallotment:...
07:00 , Aug 24, 2015 |  BioCentury  |  Strategy

Green light for GeneWeave

Roche is buying GeneWeave Biosciences Inc. to beef up the diagnostics side of its infectious disease initiative with a platform to identify bacteria - and antibiotics effective against them - in time to guide treatment...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Accelerate ID/AST Blood Culture Assay regulatory update

Accelerate received CE Mark approval for ID/AST Blood Culture Assay for use on the Accelerate ID/AST System to diagnose bacterial infections and assess antibiotic susceptibility. The in vitro test that performs culture-free genotypic and phenotypic...
08:00 , Dec 18, 2014 |  BC Innovations  |  Translation in Brief

YABAO GOES BOLD

Yabao goes bold China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target for...